Karyopharm Therapeutics Inc. shares closed at $0.10 on Monday, 2 November, their lowest close in a year and 66.8% below the previous 52-week low of $0.32 set on 14 October 2026. The shares have fallen 98.2% over the past year, excluding dividends.
Karyopharm Therapeutics' share price over the year
Over the previous 52 weeks the shares closed between $0.32 and $10.67. Over longer periods the decline extends further: down 99.1% over three years and down 99.9% over five years, excluding dividends.
What Karyopharm Therapeutics' latest figures show
What stands out is that the company's operating margin has improved even as the share price has fallen. Revenue over the twelve months to Q2 2026 was $146.6 million, up 6.8% on the year, and that growth rate was up 0.5 percentage points on the rate a quarter earlier. The trailing operating margin was negative at −56.2%, but up 27.8 percentage points from a year earlier. Below the operating line, losses still exceed revenue: the trailing net margin was −153.3%, and the company recorded a net loss of $224.7 million over the twelve months.
Where Karyopharm Therapeutics' figures sit in its own record
Today's free-cash-flow margin of −44.6% is higher than 91% of the company's own past quarterly readings, which have ranged from −23703.5% to −37.1%. Today's operating margin of −56.2% is higher than 89% of past readings, which have ranged from −100212.7% to −24.6%. Today's twelve-month revenue growth rate of 6.8% is higher than 55% of past readings, which have ranged from −67.9% to 26733.9%.
What Karyopharm Therapeutics' next report has to show
A 52-week low marks where the market's price has gone, not why. The next results will show whether the trends in the filings above support that level.